Inspections, Compliance, Enforcement, and Criminal Investigations
Kentron Health Care, Inc. - Close Out Letter 10/18/12
| Public Health Service Food and Drug Administration |
New Orleans District |
October 18, 2012
Nari Sadarangani, M.D., President
Kentron Health Care, Inc.
3604 Kelton Jackson Road
Springfield, Tennessee 37171-0120
Dear Dr. Sadarangani:
The Food and Drug Administration (FDA) completed an evaluation of your firm's corrective actions in response to our Warning Letter No. 2012-NOL-16 dated March 26, 2012. Based on our evaluation, it appears you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter does not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Ruth P. Dixon
Compliance Branch Director
New Orleans District





Department of Health and Human Services

